Table 3.
Univariable analysis of progression-free survival (PFS) and overall survival (OS).
| Characteristic | PFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Age ≥70 years (vs. <70) |
1.04 |
0.74–1.45 |
0.84 |
0.96 |
0.64–1.44 |
0.85 |
| Sex Female (vs. male) |
0.93 |
0.63–1.36 |
0.70 |
0.63 |
0.38–1.03 |
0.06 |
| Cancer type (vs. others) Head and neck cancer Urothelial cancer Renal cell cancer Gastric cancer Esophageal cancer Malignant pleural mesothelioma MSI-high solid tumors |
0.94 1.02 0.6 3.7 1.47 1.68 0.4 |
0.65–1.38 0.69–1.50 0.39–0.91 2.23–6.12 0.77–2.81 0.74–3.84 0.13–1.27 |
0.76 0.93 0.01 <0.01 0.23 0.21 0.12 |
1.05 1.93 0.27 3.01 0.95 1.13 0.21 |
0.68–1.62 1.25–2.98 0.14–0.50 1.76–5.15 0.39–2.35 0.36–3.58 0.03–1.51 |
0.83 <0.01 <0.01 <0.01 0.92 0.83 0.09 |
| ECOG performance status ≥2 (vs. 0 or 1) |
1.32 |
0.83–2.11 |
0.23 |
2.33 |
1.39–3.90 |
<0.01 |
| No. of previous regimens ≥2 (vs. 0 or 1) |
1.22 |
0.86–1.74 |
0.26 |
0.99 |
0.65–1.52 |
0.97 |
| Neutrophil/lymphocyte ratio ≥5 (vs. <5) |
1.45 |
1.09–1.93 |
0.03 |
1.88 |
1.40–2.52 |
<0.01 |
| Soluble markers sPD-1low/sPD-L1high (vs. others) |
1.79 |
1.13–2.83 |
0.01 |
1.70 |
0.99–2.91 |
0.05 |
HR, hazard ratio; CI, confidence interval; MSI, microsatellite instability; sPD-1, soluble programmed cell death–1; sPD-L1, soluble programmed cell death–ligand 1.